Malignant tumor of pancreas (disorder)
TeloVac
Year Started: 2007
- A prospective, phase III, controlled, multicentre, randomised clinical trial comparing combination Gemcitabine and Capecitabine therapy with concurrent and sequential chemoimmunotherapy using a telomerase vaccine in locally advanced and metastatic pancreatic cancer.
Samples from the TeloVac study. Includes blood samples (plasma, serum, PBMCs) and urine.
- Access:
- Closed to access
- Type:
- Clinical Trial
- Status:
- Completed
- Consent restrictions:
-
Other animal work restriction, Xenograft restriction
| Associated Data Type |
Procurement Timeframe |
| There is no associated data for this collection. |
Male
Young adult (18 - 40 years)
1 - 10 donors
| Material Type |
Extraction Procedure |
Storage Temperature |
Preservation Type |
Macroscopic Assessment |
% of Sample Set |
| There are no material preservation details for this sample set |
Female
Young adult (18 - 40 years)
11 - 100 donors
| Material Type |
Extraction Procedure |
Storage Temperature |
Preservation Type |
Macroscopic Assessment |
% of Sample Set |
| There are no material preservation details for this sample set |
Male
Adult (> 40 years)
101 - 500 donors
| Material Type |
Extraction Procedure |
Storage Temperature |
Preservation Type |
Macroscopic Assessment |
% of Sample Set |
| There are no material preservation details for this sample set |
Female
Adult (> 40 years)
501 - 1000 donors
| Material Type |
Extraction Procedure |
Storage Temperature |
Preservation Type |
Macroscopic Assessment |
% of Sample Set |
| There are no material preservation details for this sample set |
Malignant tumor of pancreas (disorder)
ViP - A prospective, phase II, double blinded, multicentre, randomised clinical trial comparing combination gemcitabine and Vandetanib therapy with gemcitabine therapy alone in locally advanced or metastatic pancreatic carcinoma.
Year Started: 2011
Clinical trial samples from the ViP study. Samples include blood (serum, plasma and cell pellet) and tissue (FFPE).
- Access:
- Closed to access
- Type:
- Clinical Trial
- Status:
- Completed
- Consent restrictions:
-
Other animal work restriction, Xenograft restriction
| Associated Data Type |
Procurement Timeframe |
| There is no associated data for this collection. |
Male
Adult (> 40 years)
11 - 100 donors
| Material Type |
Extraction Procedure |
Storage Temperature |
Preservation Type |
Macroscopic Assessment |
% of Sample Set |
| Peripheral blood mononuclear cells (PBMC) |
|
-60°C to -85°C |
N/A |
Non-affected |
75% -99% |
Male
Adult (> 40 years)
11 - 100 donors
| Material Type |
Extraction Procedure |
Storage Temperature |
Preservation Type |
Macroscopic Assessment |
% of Sample Set |
| Serum |
|
-60°C to -85°C |
N/A |
Non-affected |
75% -99% |
Male
Adult (> 40 years)
11 - 100 donors
| Material Type |
Extraction Procedure |
Storage Temperature |
Preservation Type |
Macroscopic Assessment |
% of Sample Set |
| Plasma |
|
-60°C to -85°C |
N/A |
Non-affected |
75% -99% |
Male
Adult (> 40 years)
11 - 100 donors
| Material Type |
Extraction Procedure |
Storage Temperature |
Preservation Type |
Macroscopic Assessment |
% of Sample Set |
| Tissue specimen |
Surgical procedure (procedure) |
RT |
Paraffin |
Affected |
11 - 25% |
Female
Adult (> 40 years)
11 - 100 donors
| Material Type |
Extraction Procedure |
Storage Temperature |
Preservation Type |
Macroscopic Assessment |
% of Sample Set |
| Peripheral blood mononuclear cells (PBMC) |
|
-60°C to -85°C |
N/A |
Non-affected |
75% -99% |
Female
Adult (> 40 years)
11 - 100 donors
| Material Type |
Extraction Procedure |
Storage Temperature |
Preservation Type |
Macroscopic Assessment |
% of Sample Set |
| Serum |
|
-60°C to -85°C |
N/A |
Non-affected |
75% -99% |
Female
Adult (> 40 years)
11 - 100 donors
| Material Type |
Extraction Procedure |
Storage Temperature |
Preservation Type |
Macroscopic Assessment |
% of Sample Set |
| Plasma |
|
-60°C to -85°C |
N/A |
Non-affected |
75% -99% |
Female
Adult (> 40 years)
11 - 100 donors
| Material Type |
Extraction Procedure |
Storage Temperature |
Preservation Type |
Macroscopic Assessment |
% of Sample Set |
| Tissue specimen |
Surgical procedure (procedure) |
RT |
Paraffin |
Affected |
11 - 25% |
Malignant melanoma of eye (disorder)
SUAVE - A randomised phase II study of sunitinib versus dacarbazine in the treatment of patients with metastatic uveal melanoma
Year Started: 2010
Clinical trial samples from the SUAVE study. Samples include bloods (serum, plasma and cell pellet).
- Access:
- Closed to access
- Type:
- Clinical Trial
- Status:
- Completed
- Consent restrictions:
-
Other animal work restriction, Xenograft restriction
| Associated Data Type |
Procurement Timeframe |
| There is no associated data for this collection. |
Male
Adult (> 40 years)
11 - 100 donors
| Material Type |
Extraction Procedure |
Storage Temperature |
Preservation Type |
Macroscopic Assessment |
% of Sample Set |
| Plasma |
|
-60°C to -85°C |
N/A |
Not applicable |
51 - 75% |
| Serum |
|
-60°C to -85°C |
N/A |
Not applicable |
51 - 75% |
Male
Young adult (18 - 40 years)
1 - 10 donors
| Material Type |
Extraction Procedure |
Storage Temperature |
Preservation Type |
Macroscopic Assessment |
% of Sample Set |
| Plasma |
|
-60°C to -85°C |
N/A |
Not applicable |
26 - 50% |
| Serum |
|
-60°C to -85°C |
N/A |
Not applicable |
26 - 50% |
Female
Adult (> 40 years)
11 - 100 donors
| Material Type |
Extraction Procedure |
Storage Temperature |
Preservation Type |
Macroscopic Assessment |
% of Sample Set |
| Plasma |
|
-60°C to -85°C |
N/A |
Not applicable |
26 - 50% |
| Serum |
|
-60°C to -85°C |
N/A |
Not applicable |
26 - 50% |
Female
Young adult (18 - 40 years)
1 - 10 donors
| Material Type |
Extraction Procedure |
Storage Temperature |
Preservation Type |
Macroscopic Assessment |
% of Sample Set |
| Plasma |
|
-60°C to -85°C |
N/A |
Not applicable |
26 - 50% |
| Serum |
|
-60°C to -85°C |
N/A |
Not applicable |
26 - 50% |